Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Goodwill (2016 - 2025)

Historic Goodwill for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $9.6 billion.

  • Gsk's Goodwill rose 1062.12% to $9.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 billion, marking a year-over-year increase of 1062.12%. This contributed to the annual value of $8.9 billion for FY2024, which is 535.01% up from last year.
  • Gsk's Goodwill amounted to $9.6 billion in Q3 2025, which was up 1062.12% from $9.0 billion recorded in Q2 2025.
  • Gsk's 5-year Goodwill high stood at $14.6 billion for Q3 2021, and its period low was $7.4 billion during Q2 2022.
  • Moreover, its 5-year median value for Goodwill was $8.8 billion (2023), whereas its average is $10.0 billion.
  • In the last 5 years, Gsk's Goodwill plummeted by 4900.68% in 2022 and then surged by 1299.69% in 2023.
  • Over the past 5 years, Gsk's Goodwill (Quarter) stood at $14.2 billion in 2021, then tumbled by 41.9% to $8.3 billion in 2022, then rose by 2.29% to $8.5 billion in 2023, then grew by 6.01% to $9.0 billion in 2024, then grew by 7.14% to $9.6 billion in 2025.
  • Its last three reported values are $9.6 billion in Q3 2025, $9.0 billion for Q2 2025, and $8.7 billion during Q1 2025.